Drug Funding Options for Glomerulonephritis
Many people with glomerulonephritis (GN) require immunosuppressant therapy to help manage the condition. These drugs may be funded by government drug programs, private insurance or manufacturer-supported programs, or paid for directly by the patient. We provide information, plus relevant links and forms, for each of these options.
|
Funding Option |
Eligibility |
|---|---|
|
Private Insurance |
For people who have purchased private insurance or have private insurance coverage through their employer.
|
|
Ontario Drug Benefit (ODB) & OHIP+ |
For Ontario Residents with Ontario Health Insurance Plan (OHIP) who meet one of these criteria:
|
|
Trillium Drug Program (TDP) |
Ontario Residents with OHIP, regardless of their income, may apply if they do not have private insurance or their private insurance does not cover 100% of their prescription drug costs.
|
|
Federal Non-Insured Health Benefits (NIHB) Program |
Registered First Nations and recognized Inuit people may be eligible for the NIHB. For eligibility details, visit Who is eligible for the Non-Insured Health Benefits . |
|
Interim Federal Health Program (IFHP) |
People in the following groups who are not eligible for provincial health insurance may be eligible for the IFHP:
|
|
No Medication Coverage |
|
Disclaimer: The information contained herein (“Information”) is intended for informational purposes only, and no warranty as to its accuracy is provided or implied. The Information was collected from third party sources and is subject to change without notice. Cancer Care Ontario (CCO) makes no warranty that the Information is current. The Information is intended for use by healthcare professionals to advise patients of drug funding options that may be available to them. Do not act or rely upon the Information without exercising your independent judgment or seeking the advice of a qualified professional. Anyone using the Information does so at his or her own risk. The drug funding options described on this website are managed and funded by third parties, not by CCO. Please direct any inquiries to the applicable agency/entity who manages the drug funding option.